The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

AIMS: Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lisi, Daniela, Madaudo, Cristina, Alagna, Giulia, Santoro, Marco, Rossetto, Ludovico, Siragusa, Sergio, Novo, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065844/
https://www.ncbi.nlm.nih.gov/pubmed/35355425
http://dx.doi.org/10.1002/ehf2.13897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065844/
https://www.ncbi.nlm.nih.gov/pubmed/35355425
http://dx.doi.org/10.1002/ehf2.13897

Ejemplares similares